JAIDS Journal of Acquired Immune Deficiency Syndromes This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Human Papillomavirus Infection Among Pregnant Women Living With HIV: A Systematic Review and Meta-Analysis
Conclusions: High prevalence of HPV was documented in pregnant WLWH, exceeding the prevalence among pregnant women without HIV. The limited research on this topic must be addressed with further studies to inform the use of HPV testing as a screening modality for this population as well as the role of HPV in adverse pregnancy outcomes. (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - September 18, 2022 Category: Infectious Diseases Tags: Critical Review Source Type: research

HIV Testing Services Outcomes in CDC-Funded Health Departments During COVID-19
Background: Organizations offering HIV prevention services have reported interruptions during the COVID-19 pandemic. The national extent of these interruptions and their public health impact remain largely unexplored. Methods: Using data from 60 state and local health departments, we compared HIV testing services outcomes in calendar years 2019 and 2020, including the number of Centers for Disease Control and Prevention (CDC)-funded HIV tests conducted, the percentage of persons with newly diagnosed HIV infection (ie, HIV positivity), and the percentage linked to HIV medical care within 30 days after new diagnos...
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - September 18, 2022 Category: Infectious Diseases Tags: Rapid Communication Source Type: research

Lymphocyte–CRP Ratio and CRP–Albumin Ratio as Potential Inflammation Markers in Adults With HIV
No abstract available (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - August 24, 2022 Category: Infectious Diseases Tags: Letters to the Editor Source Type: research

Time Between Viral Loads for People With HIV During the COVID-19 Pandemic
Conclusions: Early pandemic restrictions and laboratory closure significantly delayed VL monitoring. Once the laboratory reopened, nonsuppressed patients resumed normal monitoring. Suppressed patients still had a delay but no significant loss of suppression. (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - August 24, 2022 Category: Infectious Diseases Tags: Translational Research Source Type: research

Concentrations of Efavirenz, Tenofovir, and Emtricitabine in Obesity: A Cross-Sectional Study
Background: Obesity is increasing worldwide including in people living with HIV (PLWH). Antiretroviral pharmacokinetic data in obesity are limited. Objectives: To measure antiretroviral drug concentrations in obese and nonobese PLWH treated with the fixed-dose combination of efavirenz–tenofovir–emtricitabine. To determine pharmacokinetic differences across indicators of obesity and their associated immunovirological outcomes. Methods: We conducted a cross-sectional sample analysis of 2 cohort studies. We measured mid-dose efavirenz, 8-hydroxy-efavirenz, tenofovir, and emtricitabine concentrations. Ant...
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - August 24, 2022 Category: Infectious Diseases Tags: Clinical Science Source Type: research

Associative Prediction of Carotid Artery Plaques Based on Ultrasound Strain Imaging and Cardiovascular Risk Factors in People Living With HIV and Age-Matched Control Subjects of the CHACS Cohort
Conclusions: Strain elastography adds to traditional cardiovascular risk factors for identifying individuals with carotid artery plaques. (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - August 24, 2022 Category: Infectious Diseases Tags: Clinical Science Source Type: research

Brief Report: Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France
Conclusions: In this retrospective cohort study, raltegravir and dolutegravir yielded similar efficacy and safety results to efavirenz for the treatment of HIV-1/TB coinfected patients. (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - August 24, 2022 Category: Infectious Diseases Tags: Clinical Science Source Type: research

Brief Report: Impact of Antiretroviral Regimen on Pregnancy and Infant Outcomes in Women With HIV/ HBV Coinfection
Conclusion: With HBV/HIV coinfection, the risk of an APO was increased with maternal ARV compared with ZDV alone, although the differences were not statistically significant. Maternal HBeAg was associated with a significantly increased risk of APO. Infant mortality was highest with FTC + TDF + LPV/r. Early assessment of HBeAg could assist in identifying high-risk pregnancies for close monitoring. (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - August 24, 2022 Category: Infectious Diseases Tags: Clinical Science Source Type: research

Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2
Conclusions: No consistent pattern of change in biomarkers postswitch to dolutegravir + rilpivirine was observed through weeks 48 and 148 in SWORD-1/SWORD-2, suggesting no association of increased inflammation or atherogenesis with the 2-drug regimen while maintaining virologic suppression. (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - August 24, 2022 Category: Infectious Diseases Tags: Clinical Science Source Type: research

Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine
We present efficacy and safety data for islatravir and doravirine (DOR) through 96 weeks of the phase 2b trial (NCT03272347). Methods: In this randomized, double-blind, dose-ranging trial, participants initially received islatravir (0.25, 0.75, or 2.25 mg) with doravirine (100 mg) and lamivudine (3TC, 300 mg) or a fixed-dose combination of doravirine, 3TC, and tenofovir disoproxil fumarate (DOR/3TC/TDF) daily. Beginning at week 24, participants receiving islatravir stopped 3TC if HIV-1 RNA from the prior visit was (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - August 24, 2022 Category: Infectious Diseases Tags: Clinical Science Source Type: research

Effectiveness of an Interactive, Highly Tailored “Video Doctor” Intervention to Suppress Viral Load and Retain Patients With HIV in Clinical Care: A Randomized Clinical Trial
Conclusions: Positive Health Check may help male participants with HIV achieve viral suppression, and younger and older patients consistently attend HIV care. Registry Name: Positive Health Check Evaluation Trial. Trial ID: 1U18PS004967-01. URL: https://clinicaltrials.gov/ct2/show/NCT03292913. (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - August 24, 2022 Category: Infectious Diseases Tags: Implementation Science Source Type: research

A Longitudinal Mixed-Methods Examination of Positive Health Check: Implementation Results From a Type 1 Effectiveness-Implementation Hybrid Trial
Conclusions: The Positive Health Check intervention was found to fit within HIV primary care service settings, but there were some logistical challenges that needed to be addressed. Additionally, even within the context of an effectiveness trial, significant and nonlinear change in implementation climate should be expected over time. (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - August 24, 2022 Category: Infectious Diseases Tags: Implementation Science Source Type: research

HIV Pre-exposure Prophylaxis Uptake and Continuation Among Key Populations in Cameroon: Lessons Learned From the CHAMP Program
Introduction: Pre-exposure prophylaxis (PrEP) is proven to be a highly effective HIV prevention method for key populations. However, its scale-up in resource-limited settings remains suboptimal. This paper seeks to describe PrEP initiation and continuation among key populations in Cameroon. Methodology: From June 2019 through October 2020, we collected routine program data on PrEP uptake and continuation among female sex workers (FSWs) and men who have sex with men (MSM) in the Continuum of prevention, care and treatment of HIV/AIDS with Most-at-risk Populations (CHAMP) program in Cameroon. PrEP was offered to c...
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - August 24, 2022 Category: Infectious Diseases Tags: Implementation Science Source Type: research

Employment as HIV Prevention: An Employment Support Intervention for Adolescent Men Who Have Sex With Men and Adolescent Transgender Women of Color
Conclusion: Work2Prevent is one of the first structural primary HIV interventions to specifically focus on adolescent employment readiness. Findings suggest Work2Prevent is feasible and acceptable, improved adolescent employment outcomes, and reduced HIV risk associated with transactional sex work. Our study underscores the need for alternative pathways, such as addressing socioeconomic determinants, to prevent adolescent HIV infection. (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - August 24, 2022 Category: Infectious Diseases Tags: Prevention Research Source Type: research

Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial
Conclusions: Over a third of women initiating PrEP and reporting ongoing use at the final trial visit had evidence of recent drug exposure. Clinical trials may serve as an entry point for PrEP initiation among women at substantial risk for HIV infection with referral to local facilities for ongoing access at trial end. Clinical trial number: NCT02550067. (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - August 24, 2022 Category: Infectious Diseases Tags: Prevention Research Source Type: research